caa a22 4500 46911617X CHVBK 20180323133125.0 cr unu---uuuuu 170328e19920101xx s 000 0 eng 10.1007/BF00172456 doi (NATIONALLICENCE)springer-10.1007/BF00172456 Cisplatin-based chemotherapy in primary central nervous system germ cell tumors [Elektronische Daten] [Shreyaskumar Patel, Jan Buckner, W. Smithson, Bernd Scheithauer, Robert Groover] We report a retrospective review of our experience with cisplatin-based chemotherapy in eight patients (ages 9-44 years) with histologically confirmed primary central nervous system germ cell tumors. Five patients received chemotherapy as the primary treatment, radiation therapy being administered either at completion of chemotherapy or between chemotherapy courses. Three patients received cisplatin-based chemotherapy for recurrent disease after prior radiation therapy and/or surgery. Four of five patients treated with chemotherapy at diagnosis are in complete remission at 11-14 months from diagnosis. The remaining patient twice achieved complete remission prior to dying of progressive disease 16 months after diagnosis. Two of three patients treated with chemotherapy for recurrent disease are in complete remission at 20 and 26 months; the remaining patient deteriorated after the first cycle of chemotherapy and expired six months thereafter. Overall, of seven patients evaluable for response, five achieved complete remission with chemotherapy alone, and two with chemotherapy and radiation therapy. Our results confirm previous reports of high complete remission rates utilizing cisplatin-based chemotherapy in conjunction with radiation therapy. Prospective evaluation of cisplatin-based chemotherapy followed by radiation therapy is warranted. Kluwer Academic Publishers, 1992 germ cell tumors nationallicence cisplatin nationallicence chemotherapy nationallicence pineal tumor nationallicence brain neoplasm nationallicence Patel Shreyaskumar Division of Medical Oncology, Mayo Clinic, 55905, Rochester, MN, USA aut Buckner Jan Division of Medical Oncology, Mayo Clinic, 55905, Rochester, MN, USA aut Smithson W. Division of Pediatric Hematology/Oncology, Mayo Clinic, 55905, Rochester, MN, USA aut Scheithauer Bernd Division of Surgical Pathology, Mayo Clinic, 55905, Rochester, MN, USA aut Groover Robert Division of Pediatric Neurology, Mayo Clinic, 55905, Rochester, MN, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 12/1(1992-01-01), 47-52 0167-594X 12:1<47 1992 12 11060 https://doi.org/10.1007/BF00172456 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172456 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Patel Shreyaskumar Division of Medical Oncology, Mayo Clinic, 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Buckner Jan Division of Medical Oncology, Mayo Clinic, 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Smithson W. Division of Pediatric Hematology/Oncology, Mayo Clinic, 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Scheithauer Bernd Division of Surgical Pathology, Mayo Clinic, 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Groover Robert Division of Pediatric Neurology, Mayo Clinic, 55905, Rochester, MN, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 12/1(1992-01-01), 47-52 0167-594X 12:1<47 1992 12 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer